Braxia Scientific Corp. (BRAXF) Stock
Braxia Scientific Corp. functions as a medical research entity that also runs clinics, offering ketamine therapies to individuals suffering from depression and linked conditions.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About Braxia Scientific Corp.
Braxia Scientific Corp. functions as a medical research entity that also runs clinics, offering ketamine therapies to individuals suffering from depression and linked conditions. Beyond its clinical services, the company is actively engaged in discovering and bringing to market novel pharmaceutical compounds and innovative delivery methods. Leveraging its intellectual property development platform, Braxia Scientific innovates by developing derivatives of ketamine and psilocybin, in addition to other psychedelic substances. The organization further owns and operates several multidisciplinary clinics focused on treating a broad spectrum of mental health disorders. Braxia Scientific Corp.'s main office is located in Mississauga, Ontario.
Braxia Scientific Corp. (BRAXF) stock trades at $0.00 with a market capitalization of $28328. The stock is valued at a price-to-earnings (P/E) ratio of -0.09, price-to-book of 0.01, price-to-sales of 0.01. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.
On profitability, Braxia Scientific Corp. generates a return on equity (ROE) of -254.58%, return on capital employed of -430.88%, an operating margin of -174.06%, a net profit margin of -650.00%.
Official website: www.braxiascientific.com